Status: Recruiting
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
The study is being conducted to evaluate the efficacy, and safety of Lutetium (177Lu) Oxodotreotide Injection in subjects with advanced gastrointestinal pancreatic neuroendocrine tumors.
Participants needed: 220
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Jiangsu HengRui Medicine Co., Ltd.Updated: May 19, 2026Locations: 2
Eligibility criteria
Able and willing to provide a written informed consent; [+3]
Central nervous system metastasis is known. Patients who have previously receive... [+3]